About Acute Myeloid Leukemia
Acute myeloid leukemia, also known as acute myelogenous leukemia, is a hematopoietic disorder that starts either in hematopoietic stem cells or lineage-specific progenitor cells. Neoplasms arise from bone marrow, however, it spreads quickly into the blood. In the later stages of the disorder, it spreads to spleen, lymph node, liver, brain, spinal cord and testicles. Clonal expansion of the myeloid blasts and the loss of normal hematopoiesis are the main characteristic of acute myeloid leukemia. The disease affects the elderly people with age of 67 years. Fever, pallor, fatigue and hemorrhages are some of the clinical symptoms of the disease. Smoking, exposure to certain chemicals such as benzene, exposure to radiations, cancer patients, who are treated with chemotherapy, blood disorder or genetic mutations are some of the risk factors for the development of acute myeloid leukemia in patients.
TechNavio's analysts forecast the Global Acute Myeloid Leukemia Therapeutics market to grow at a CAGR of 19.75 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Acute Myeloid Leukemia Therapeutics market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic, off-label and branded therapies used for treatment.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Acute Myeloid Leukemia Therapeutics market. In addition, the report discusses the major drivers that influence the growth of the market and also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
TechNavio's report, Global Acute Myeloid Leukemia Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC regions and the EMEA regions; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Bristol Myers Squibb
• Celgene
• Johnson & Johnson
• Pfizer
Other Prominent Vendors
• Abbott
• Ambit BioSciences
• Amgen
• Astex Pharmaceuticals
• AstraZeneca
• Baxter Healthcare
• Bayer
• Boehringer Ingelheim
• Celator Pharmaceuticals
• Chroma Therapeutics
• Chugai Pharmaceutical
• CTI Biopharma
• Cyclacel Pharmaceuticals
• Eisai
• F. Hoffmann-La Roche
• Immune Pharmaceuticals
• Innate Pharma
• Kanisa Pharmaceuticals
• Meda
• Merck Sharp & Dohme
• Midas Pharmaceuticals
• Neovii Biotech
• Nippon Shinyaku
• Novo Nordisk
• Sanofi
• Sunesis Pharmaceuticals
• Teva Pharmaceutical
• Tolero Pharmaceuticals
Market Driver
• Unmet Needs in the Market
• For a full, detailed list, view our report
Market Challenge
• Expensive Treatment
• For a full, detailed list, view our report
Market Trend
• Expected Entry of Novel Therapies
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Cytoxan
04.1.2 Vidaza
04.1.3 Dacogen
04.1.4 Idamycin PFS
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Disease Overview
07.1 Understanding the Disease
07.2 Etiology and Risk Factors
07.3 Pathophysiology
07.4 Epidemiology
07.5 Classification
07.5.1 FAB Classification
07.5.2 WHO Classification
07.6 Diagnosis
07.6.1 Blood Samples
07.6.2 Bone Marrow Samples
07.6.3 Spinal Fluid
07.6.4 CBC and Peripheral Smear
07.6.5 Blood Chemistry and Coagulation Tests
07.6.6 Microscopic Exams
07.6.7 Cytochemistry
07.6.8 Flow Cytometry and Immunohistochemistry
07.6.9 Cytogenetics
07.6.10 FISH and PCR
07.6.11 X-Ray
07.6.12 CT Scan
07.6.13 Ultrasound
07.6.14 MRI Scan
07.7 Treatment and Management
07.7.1 Induction Therapy
07.7.2 Post Remission Therapy
07.8 Economic Burden
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis
09. Market Segmentation by Class of Drugs
09.1 Alkylating Agent
09.2 Cytotoxic Antibiotic
09.3 Topoisomerase Inhibitor
09.4 Others
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Pipeline Portfolio
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.2.1 Celgene
19.2.2 Johnson & Johnson
19.2.3 Pfizer
19.2.4 Bristol Myers Squibb
19.3 Other and Future Prominent Vendors
20. Key Vendor Analysis
20.1 Bristol Myers Squibb
20.1.1 Key Facts
20.1.2 Business Description
20.1.3 Business Segmentation
20.1.4 Revenue by Business Segmentation
20.1.5 Revenue Comparison 2013 and 2014
20.1.6 Sales by Geography
20.1.7 Business Strategy
20.1.8 Key Developments
20.1.9 SWOT Analysis
20.2 Celgene
20.2.1 Key Facts
20.2.2 Business Description
20.2.3 Business Segmentation
20.2.4 Revenue by Business Segmentation
20.2.5 Revenue Comparison 2013 and 2014
20.2.6 Sales by Geography
20.2.7 Business Strategy
20.2.8 Key Developments
20.2.9 SWOT Analysis
20.3 Johnson and Johnson
20.3.1 Key Facts
20.3.2 Business Description
20.3.3 Business Segmentation
20.3.4 Revenue by Business Segmentation
20.3.5 Revenue Comparison 2013 and 2014
20.3.6 Sales by Geography
20.3.7 Business Strategy
20.3.8 Key Developments
20.3.9 SWOT Analysis
20.4 Pfizer
20.4.1 Key Facts
20.4.2 Business Description
20.4.3 Business Segmentation
20.4.4 Revenue by Business Segmentation
20.4.5 Revenue Comparison 2013 and 2014
20.4.6 Sales by Geography
20.4.7 Business Strategy
20.4.8 Key Developments
20.4.9 SWOT Analysis
23. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Snapshot of Acute Myeloid Leukemia
Exhibit 3: Percentage of Acute Myeloid Leukemia Cases in Comparison with Other Types of Leukemia in the US 2014
Exhibit 4: FAB Classification of Acute Myeloid Leukemia
Exhibit 5: FAB Classification of Acute Myeloid Leukemia and the Percentage of Patients in Each Class
Exhibit 6: Percentage Distribution of Acute Myeloid Leukemia Patients According to the FAB Classification
Exhibit 7: The WHO Classification of Acute Myeloid Leukemia
Exhibit 8: Treatment Options for Acute Myeloid Leukemia
Exhibit 9: Treatment Options for Relapsed Acute Myeloid Leukemia
Exhibit 10: Snapshot of the Economic Burden of Acute Myeloid Leukemia
Exhibit 11: Cost Per Patient in Different Treatment Cycles in the US (2012)
Exhibit 12: Cost Per Patient in Different Treatment Cycles in the UK (2012)
Exhibit 13: Snapshot of the Global Acute Myeloid Leukemia Therapeutics Market, 2014
Exhibit 14: Global Acute Myeloid Leukemia Therapeutics Market 2014-2019 (US$ million)
Exhibit 15: Global Acute Myeloid Leukemia Therapeutics Market Segmentation by Class of Drugs
Exhibit 16: Global Acute Myeloid Leukemia Therapeutics Market Segmentation by Class of Drugs 2014
Exhibit 17: Global Acute Myeloid Leukemia Therapeutics Market by Geographical Segmentation 2014
Exhibit 18: Buying Criteria of Global Acute Myeloid Leukemia Therapeutics Market
Exhibit 19: Phase III Pipeline Molecules for Acute Myeloid Leukemia
Exhibit 20: Global Acute Myeloid Leukemia Therapeutics Market Share Analysis 2014
Exhibit 21: Authorization Details of Vidaza
Exhibit 22: Regulatory History of Dacogen
Exhibit 23: Authorization Details of Dacogen
Exhibit 24: Bristol-Myers Squibb: Business Segmentation 2014
Exhibit 25: Bristol-Myers Squibb: Business Segmentation by Revenue 2013 and 2014 (US$ million)
Exhibit 26: Bristol-Myers Squibb: Sales by Geography (in US$ million)
Exhibit 27: Celgene: Business Segmentation by Revenue 2013 and 2014
Exhibit 28: Celgene: Sales by Geography 2014 (Pharmaceuticals Division)
Exhibit 29: Celgene: Sales by Geography 2014 (Diagnostics Division)
Exhibit 30: Johnson & Johnson: Business Segmentation by Revenue 2014
Exhibit 31: Johnson & Johnson: Business Segmentation by Revenue 2013 and 2014 (US$ million)
Exhibit 32: Johnson & Johnson: Sales by Geography 2014
Exhibit 33: Pfizer: Business Segmentation
Exhibit 19: Pfizer: Revenue by Business Segmentation 2014
Exhibit 20: Pfizer: Revenue by Business Segmentation 2013 and 2014 (US$ million)
Exhibit 21: Pfizer: Revenue by Geographical Segmentation 2014
